�Today's decisiveness by the Medicines and Healthcare products Regulatory
Agency (MHRA) to approve the reclassification of azithromycin for the
discourse of chlamydia infection will mean convenient and effective care for
patients, aforementioned the Royal Pharmaceutical Society of Great Britain (RPSGB).
Azithromycin, presently licensed as a prescription-only medicine, is expected
to be useable for sale from pharmacies without a prescription by and by this
year.
Azithromycin is the first oral antibiotic to be approved for
reclassification. It will be available for people 16 years and over if they
have tested positive for the infection through an sanctioned standard test and
feature no symptoms. It will also be available for their sexual partners.
Howard Duff, RPSGB's Director for England, aforesaid: "Pharmacists already
play an important role in the provision of sexual health services, and have
done so for many days. Reclassifying azithromycin will dilate on existing
services and improve memory access to chlamydia screening and treatment for
patients.
"Chlamydia infection rates are increasing, particularly in those under 25
age of years. The development of allow sexual health services for this
group should effect in higher rates of detection of sexually inherited
infections and improved sentience of the importance of practising safe sex."
The Royal Pharmaceutical Society of Great Britain is the
professional and regulatory consistence for pharmacists in England, Scotland and
Wales. It also regulates pharmacy technicians on a voluntary ground, which
is expected to become statutory under anticipated legislation. The
primary objectives of the Society ar to lead, regulate,
